Drug profile

The FDA adverse-event record for Fatty Acid/Fish Oil Supplement

122 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Fatty Acid/Fish Oil Supplement. See the species affected, top reactions, and outcomes below.

122
adverse-event reports
2.5%
death-coded share
Dog
most-reported species
29
Emesis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
122
Total Reports
3
Deaths Reported
2.5%
Death Rate

Active Ingredients

Fatty Acid/Fish Oil Supplement

Administration Routes

OralUnknown

Species Affected

Dog 120
Cat 2

Most Affected Breeds

Retriever - Labrador 16
Retriever - Golden 9
Shepherd Dog - German 6
Shih Tzu 5
Pit Bull 5
Terrier - Yorkshire 4
Boxer (German Boxer) 4
Doberman Pinscher 4
Collie - Border 4
Retriever (unspecified) 3

Most Reported Reactions

Emesis 29
Vomiting 22
Lethargy (see also Central nervous system depression in 'Neurological') 21
Lack of efficacy - NOS 14
Diarrhoea 11
Other abnormal test result NOS 7
Seizure NOS 6
Pruritus 4
Decreased appetite 4
Elevated alanine aminotransferase (ALT) 4
Ataxia 4
Behavioural disorder NOS 4

Outcome Breakdown

Recovered/Normal
57 (46.7%)
Outcome Unknown
28 (23.0%)
Ongoing
21 (17.2%)
Recovered with Sequela
13 (10.7%)
Died
2 (1.6%)
Euthanized
1 (0.8%)

Fatty Acid/Fish Oil Supplement Adverse Event Insights

122 reports name Fatty Acid/Fish Oil Supplement; 3 recorded a death outcome (2.5% of reported events, not a population-level mortality rate). Active ingredient: Fatty Acid/Fish Oil Supplement. Administration routes: Oral, Unknown.

By species: Dog (120 reports), Cat (2 reports). By breed: Retriever - Labrador (16), Retriever - Golden (9), Shepherd Dog - German (6).

Leading clinical signs: Emesis (29), Vomiting (22), Lethargy (see also Central nervous system depression in 'Neurological') (21), Lack of efficacy - NOS (14). Outcome, 122 coded reports: Recovered/Normal leads at 46.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.